Trial Profile
A Phase 2, 52 Week, Single Center, Open-Label Study Utilizing Imaging Techniques and Evaluating the Safety and Efficacy of SM04690 Injectable Suspension for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Nov 2021
Price :
$35
*
At a glance
- Drugs Lorecivivint (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Biosplice Therapeutics; Samumed
- 15 Nov 2021 Status changed from completed to discontinued.
- 12 Jan 2021 Status changed from recruiting to completed.
- 17 Jul 2020 Planned End Date changed from 1 Jul 2020 to 1 Dec 2020.